(INGR) Ingredion - Overview
Sector: Consumer Defensive | Industry: Packaged Foods | Exchange: NYSE (USA) | Market Cap: 6.397m USD | Total Return: -25.7% in 12m
Avg Turnover: 77.0M
EPS Trend: 85.2%
Qual. Beats: 0
Rev. Trend: -96.7%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Ingredion Incorporated (NYSE: INGR) is a global manufacturer of ingredient solutions, specializing in the processing of corn and other starch-based materials. The company produces a diverse portfolio of sweeteners, starches, and biomaterials used across the food, beverage, paper, and pharmaceutical industries. Its business model relies on wet milling technology to convert raw agricultural commodities into high-value specialty ingredients and industrial additives.
The company operates through three primary segments: Texture & Healthful Solutions, and two regional Food & Industrial Ingredients divisions covering North America and Latin America. As a major player in the agricultural products sector, Ingredion’s profitability is closely tied to the crush spread, or the margin between the cost of raw corn and the combined selling price of its finished products and co-products like corn gluten and refined oil.
Ingredion’s industrial applications extend beyond nutrition into biodegradable plastics, construction materials, and water filtration systems. Investors interested in deeper fundamental metrics can find additional data on ValueRay. Founded in 1906 and formerly known as Corn Products International, the firm maintains its headquarters in Westchester, Illinois.
- Specialty ingredient mix shift improves gross margins over bulk sweetener sales
- Corn price volatility impacts raw material procurement costs and operating profit
- Growth in plant-based and healthful solutions drives higher value-added revenue
- Industrial starch demand fluctuates with global construction and paper manufacturing cycles
- Foreign exchange headwinds in Latin American markets affect consolidated earnings growth
| Net Income: 674.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -3.65 > 1.0 |
| NWC/Revenue: 31.23% < 20% (prev 29.66%; Δ 1.57% < -1%) |
| CFO/TA 0.11 > 3% & CFO 900.0m > Net Income 674.0m |
| Net Debt (1.09b) to EBITDA (1.16b): 0.94 < 3 |
| Current Ratio: 2.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.4m) vs 12m ago -1.83% < -2% |
| Gross Margin: 24.49% > 18% (prev 25.00%; Δ -0.50% > 0.5%) |
| Asset Turnover: 93.50% > 50% (prev 98.57%; Δ -5.06% > 0%) |
| Interest Coverage Ratio: 25.30 > 6 (EBIT TTM 936.0m / Interest Expense TTM 37.0m) |
| A: 0.28 (Total Current Assets 3.52b - Total Current Liabilities 1.28b) / Total Assets 7.93b |
| B: 0.72 (Retained Earnings 5.70b / Total Assets 7.93b) |
| C: 0.12 (EBIT TTM 936.0m / Avg Total Assets 7.70b) |
| D: 1.27 (Book Value of Equity 4.42b / Total Liabilities 3.48b) |
| Altman-Z'' = 6.36 = AAA |
| DSRI: 1.08 (Receivables 1.36b/1.28b, Revenue 7.20b/7.36b) |
| GMI: 1.02 (GM 25.00% / 24.49%) |
| AQI: 0.96 (AQ_t 0.23 / AQ_t-1 0.24) |
| SGI: 0.98 (Revenue 7.20b / 7.36b) |
| TATA: -0.03 (NI 674.0m - CFO 900.0m) / TA 7.93b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of June 08, 2026, the stock is trading at USD 99.98 with a total of 617,178 shares traded.
Over the past week, the price has changed by -1.44%,
over one month by -6.87%,
over three months by -11.18% and
over the past year by -25.65%.
Ingredion has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold INGR.
- StrongBuy: 2
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 121.9 | 21.9% |
P/E Trailing = 9.7538
P/E Forward = 9.3284
P/S = 0.8887
P/B = 1.4459
P/EG = 1.2691
Revenue TTM = 7.20b USD
EBIT TTM = 936.0m USD
EBITDA TTM = 1.16b USD
Long Term Debt = 1.74b USD (from longTermDebt, last quarter)
Short Term Debt = 83.0m USD (from shortTermDebt, last quarter)
Debt = 2.01b USD (from shortLongTermDebtTotal, last quarter) + Leases 181.0m
Net Debt = 1.09b USD (calculated: Debt 2.01b - CCE 918.0m)
Enterprise Value = 7.48b USD (6.40b + Debt 2.01b - CCE 918.0m)
Interest Coverage Ratio = 25.30 (Ebit TTM 936.0m / Interest Expense TTM 37.0m)
EV/FCF = 10.02x (Enterprise Value 7.48b / FCF TTM 747.0m)
FCF Yield = 9.98% (FCF TTM 747.0m / Enterprise Value 7.48b)
FCF Margin = 10.38% (FCF TTM 747.0m / Revenue TTM 7.20b)
Net Margin = 9.36% (Net Income TTM 674.0m / Revenue TTM 7.20b)
Gross Margin = 24.49% ((Revenue TTM 7.20b - Cost of Revenue TTM 5.43b) / Revenue TTM)
Gross Margin QoQ = 22.38% (prev 24.47%)
Tobins Q-Ratio = 0.94 (Enterprise Value 7.48b / Total Assets 7.93b)
Interest Expense / Debt = 1.84% (Interest Expense 37.0m / Debt 2.01b)
Taxrate = 24.42% (220.0m / 901.0m)
NOPAT = 707.5m (EBIT 936.0m * (1 - 24.42%))
Current Ratio = 2.76 (Total Current Assets 3.52b / Total Current Liabilities 1.28b)
Debt / Equity = 0.45 (Debt 2.01b / totalStockholderEquity, last quarter 4.42b)
Debt / EBITDA = 0.94 (Net Debt 1.09b / EBITDA 1.16b)
Debt / FCF = 1.46 (Net Debt 1.09b / FCF TTM 747.0m)
Total Stockholder Equity = 4.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.76% (Net Income 674.0m / Total Assets 7.93b)
RoE = 15.57% (Net Income TTM 674.0m / Total Stockholder Equity 4.33b)
RoCE = 15.42% (EBIT 936.0m / Capital Employed (Equity 4.33b + L.T.Debt 1.74b))
RoIC = 11.10% (NOPAT 707.5m / Invested Capital 6.37b)
WACC = 5.47% (E(6.40b)/V(8.40b) * Re(6.75%) + D(2.01b)/V(8.40b) * Rd(1.84%) * (1-Tc(0.24)))
Discount Rate = 6.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.83 | Cagr: -1.35%
[DCF] Terminal Value 73.10% ; FCFF base≈838.6m ; Y1≈735.4m ; Y5≈594.2m
[DCF] Fair Price = 134.0 (EV 9.54b - Net Debt 1.09b = Equity 8.45b / Shares 63.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 85.16 | EPS CAGR: 11.01% | SUE: -0.49 | # QB: 0
Revenue Correlation: -96.70 | Revenue CAGR: -5.43% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.76 | Chg30d=-5.23% | Revisions=-40% | Analysts=6
EPS next Quarter (2026-09-30): EPS=2.89 | Chg30d=-4.55% | Revisions=-60% | Analysts=6
EPS current Year (2026-12-31): EPS=10.82 | Chg30d=-5.02% | Revisions=-64% | GrowthEPS=-2.8% | GrowthRev=+0.5%
EPS next Year (2027-12-31): EPS=11.61 | Chg30d=-3.28% | Revisions=-64% | GrowthEPS=+7.2% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -64%